{"schema_version":"secwatch.filing_event.v1","accession":"0000875320-24-000012","form_type":"8-K","ticker":"VRTX","cik":"0000875320","company_name":"VERTEX PHARMACEUTICALS INC / MA","filed_at":"2024-02-05T23:59:59+00:00","discovered_at":"2026-05-14T18:03:27.103609+00:00","generated_at":"2026-06-06T09:35:51.644718+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"confidence":"high","headline":"Vertex Q4/FY23 revenue $2.52B/$9.87B; FY24 guidance $10.55-$10.75B; vanza triple and VX-548 NDAs by mid-2024","bullets":["FY23 product revenue $9.87B (+11% YoY); Q4 revenue $2.52B (+9% YoY).","FY24 product revenue guidance $10.55-$10.75B, reflecting CF growth and CASGEVY launch.","Completed pivotal studies for vanzacaftor triple (CF) and VX-548 (acute pain); NDAs to FDA by mid-2024.","CASGEVY approved in U.S., Great Britain, KSA, Bahrain; CHMP positive opinion; activated ATCs.","VX-880 Phase 1/2 study on protocol-specified pause; VX-264 advanced to Part B."],"urls":{"canonical":"https://secwatch.observer/filing/0000875320-24-000012","json":"https://secwatch.observer/filing/0000875320-24-000012.json","markdown":"https://secwatch.observer/filing/0000875320-24-000012.md","text":"https://secwatch.observer/filing/0000875320-24-000012.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/875320/000087532024000012/0000875320-24-000012-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/875320/000087532024000012/vrtx-20240205.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-06T09:35:51.644718+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"6011e0d69e8690db534591e6610cd1fe587018e9","claim":"VERTEX PHARMACEUTICALS INC / MA updated its the fourth quarter and full year ended December 31, 2023 guidance (raised).","evidence_excerpt":"On February 5, 2024, we issued a press release in which we reported our consolidated financial results for the three and twelve months ended December 31, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/875320/000087532024000012/0000875320-24-000012-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter and full year ended December 31, 2023"},{"label":"Guidance","value":"raised"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}